ReviewNature communications2022
Immune-related adverse events and the balancing act of immunotherapy.
Review in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.Nature communications · 2024Pooled it
- Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis.Immunotherapy · 2024Pooled it
- 4-1BBCell reports. Medicine · 2025Trial
- Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.The oncologist · 2025Trial
- Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.Oncoimmunology · 2024Trial
- Complex cardiac overlap: immune checkpoint inhibitor myocarditis in hypertrophic obstructive cardiomyopathy with subsequent NSTEMI.Cardio-oncology (London, England) · 2026Article
- Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population.Clinical and translational radiation oncology · 2026Article
- Selective chemical reprogramming of tumor-associated macrophages.Nature chemical biology · 2026Article
- Tumor immune cell targeting chimeras reprogram tumor-associated macrophages.Nature chemical biology · 2026Article
- Characteristics of Immune Checkpoint Inhibitor-Related Hepatotoxicity Based on the Baseline Liver Function.Cancer research and treatment · 2026Article
- Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.NPJ precision oncology · 2026Article
- Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures.Immuno-oncology technology · 2026Article
- Cold Atmospheric Plasma-Activated Decellularized Extracellular Matrix Gel as a Tumor-Infiltrating Immunoactivation Platform for Post-Surgical Cancer Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion.Cell reports. Medicine · 2026Article
- Pembrolizumab-induced oral erosive lichen planus treated with dupilumab.JAAD case reports · 2026Article
- Transcriptomic Determinants of Circulating Immunity Predict Immune-Related Adverse Events (irAEs) in Cancer Patients Receiving PD-1/PD-L1 Blockade.Thoracic cancer · 2026Article
- Pembrolizumab-associated hemophagocytic lymphohistiocytosis in recurrent metastatic squamous cell carcinoma of the ovary arising in a teratoma.Gynecologic oncology reports · 2026Article
- Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026Review
- Immune Checkpoint Inhibitor Therapy and Acute Coronary Syndrome: A Review of Mechanisms and Management.Journal of the American Heart Association · 2026Review
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.